Category: CannabisNewsWire Release

420 with CNW — California Moves to Crackdown on Hemp Intoxicants

It has become clear in recent years that obtaining a cannabis license is both expensive and complicated. As a result, many people have found it easier to sell intoxicating products, such as hemp THC beverages. However, this trend may be shifting, especially in California.

Hemp THC beverages are drinks that contain hemp-derived delta-9 THC. You might be wondering how this is possible given the federal law that restricts THC content to 0.3%. Interestingly, these beverages can still be intoxicating without exceeding this limit. For instance, a drink containing 5 to 10 milligrams of hemp-derived THC can be intoxicating while still maintaining a THC concentration below 0.3%, depending on its weight.

California Governor Gavin Newsom issued an order in April for the Alcoholic Beverage Control (ABC) and the Public Health Department (CDPH) to ensure hemp products sold in the state adhere to the law. The initiative, titled California Takes Action to Protect Youth from Illegal Hemp Products, emphasizes the need to prevent mislabeled and misleading products from reaching the market, particularly to safeguard children’s health.

The directive highlighted concerns about highly intoxicating hemp beverages appearing in retail stores, which could easily end up in the hands of minors. Hemp products, distinct from those in the legal market, must adhere to stringent consumer safety regulations, including precise labeling requirements. Failure to comply with these regulations is illegal and can lead to license revocation.

Following the directive, both ABC and CDPH issued general warnings to entities about potentially illegal hemp products.

Last week, CDPH specifically warned consumers against drinking hemp-infused sodas under the Mary Jones branding, alleging that the drinks contained isolate of delta-9 THC. As per the CDPH, state law prohibits the inclusion of THC isolate as a component in hemp products.

This warning, which indicates that CDPH views goods containing THC isolates could be dangerous, might have a big impact on the California hemp THC beverage market. The future actions of CDPH remain uncertain, especially regarding companies that produce hemp THC drinks without using THC isolates. State law grants CDPH and other regulators substantial authority to target companies selling “misbranded” or “adulterated” products. These terms can be interpreted broadly, potentially encompassing any product with intoxicating cannabinoids.

Under California law, “THC” broadly consists of:

  • tetrahydrocannabinolic acid
  • tetrahydrocannabinol of any kind regardless of how they are derives (the CDPH may exclude certain isomers from this definition)
  • any other cannabis compound, except CBD, that CDPH determines to be intoxicating.

This definition indicates that CDPH may examine any psychoactive cannabinoid, not just isolate of delta-9 THC. Additionally, there are federal considerations to keep in mind. Recent proposed amendments to Farm Bill 2024 aim to limit intoxicating cannabis compounds. While the amendments do not specify a restrictive milligram cap for hemp THC beverages, they do exclude products with “quantifiable levels” of THC or other intoxicating cannabis compounds from the definition of hemp. The exact meaning of “quantifiable levels” will be determined by federal regulators, which could result in regulations that effectively ban intoxicating hemp THC drinks.

The actions taken by California regulators to crackdown on hemp intoxicants could help to clarify the boundaries between the THC products from licensed companies in various jurisdictions, such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), and products synthesized from hemp.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Explores Views of Americans on Cannabis Legalization

As the United States moves closer to rescheduling and legalizing cannabis, critical questions emerge about who should benefit from these changes and who is best suited to craft equitable cannabis policies. Big businesses frequently have a big say in what laws are passed, and the cannabis industry seems to be no exception. But who, in the opinion of Americans, ought to have more influence over cannabis laws?

A recent survey by the Parabola Center, a nonpartisan think tank made up of experts in drug policy and law who advocate for marijuana legalization with a special emphasis on small enterprises and individuals, provides insight into public opinion. When respondents were asked who they trusted to develop effective marijuana policies, they provided the following responses:

  • 67%: individuals with firsthand experience
  • 56%: cannabis users
  • 55%: social-equity advocates
  • 24%: representatives from pharmaceutical companies
  • 22%: federal government
  • 18%: executives from the tobacco industry
  • 13%: executives from the alcohol industry

It makes sense that people have little faith in executives in the alcohol and tobacco industries, given the harmful effects of their products. Furthermore, as their regular customer base shrinks, a few of these businesses are keen to join the cannabis space.

When asked about their top concerns regarding marijuana policy, respondents said the following:

  • 68%: promoting social equity
  • 68%: ending cannabis-related arrests
  • 65%: ensuring access to marijuana
  • 49%: fostering a sharing society
  • 42%: preserving cannabis culture
  • 27%: keeping cannabis illegal

The war on drugs, including marijuana prohibition, disproportionately harmed certain communities. Many believe that fair policies could help address some of the injustices caused by past enforcement. In fact, according to 61% of respondents, legalization should help individuals who have been negatively impacted by current prohibitions.

President Joseph Biden has also acknowledged the negative impacts caused by outdated cannabis policies. He stated in 2022 while announcing a review of how marijuana is classified, that many lives have been upended because of failed cannabis policy approaches, and it was time to make the mistakes right.

When asked who should benefit from cannabis legalization, respondents identified the following top three groups:

  • 85%: people using marijuana for medicinal purposes
  • 73%: workers in the marijuana industry
  • 63%: recreational users

Conversely, the least-favored groups included alcohol companies, the tobacco industry, large corporations and pharmaceutical companies.

The survey, conducted in September 2023, involved 404 U.S. adults. Although not extensive, it may be one of the first surveys to explore this particular angle of marijuana policy and legalization.

Entities such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) will be pleased to see that the general public sentiment is in favor of ending cannabis prohibition at the federal level and allowing experienced industry professionals to be in charge of policy making and implementation.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Alternative Products Expo to Present Fresh Ideas and Products in Houston

The Alternative Products Expo by ZJ Events is coming to George R. Brown Center, Houston, June 20-22, 2024. Houston has emerged as a thriving center of smoke shops, with its rich food, culture, and resourceful connectivity, and the Alternative Products Expo will witness a large crowd of traders, manufacturers, and enthusiasts from all over the country.

ZJ Events is a pioneer in organizing expos for the CBD community where they discover novel innovations and get updates on new industry trends and regulations. Traders can leverage the event platform to get the best show-exclusive deals limited to the event. Attendees can explore, connect, and collaborate with industry veterans and peers in an exciting environment with immense learning opportunities.

The Alternative Product category includes herbal products, energy boosts, cannabis derivatives, mood enhancers, vape products, wellness products, and dietary supplements, to name a few. A go-to event for smoke shop owners, the expo offers unique products and fresh ideas for the local cannabis community. The canna enthusiasts can find exciting alternative products and their ancillary accessories & services at the expo.

Exhibitors can showcase their unique products at the exhibit booths. The event offers an expansive platform for traders, retailers, and e-commerce businesses looking to expand their business. As a part of their marketing campaign, the Alternative Products Expo organizers will ensure direct introductions to Shop owners, gas station owners, and retailers. Traders can maximize their brand visibility, build long-term ties with investors, and leverage the expo’s networking and marketing strategies for better ROI.

The event will also bring together the local cannabis community in and around Houston, boosting common interests and business collaborations. It’s time to deepen connections with the cannabis community, discover the most exciting products in the market, and connect with a vibrant cannabis community at the Alternative Products Expo.

Trinity Hemp is the presenting sponsor of Alternative Products Expo Houston.

To learn more, please visit https://cnw.fm/bJkpI

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Says Cannabis Terpenes Equal to Morphine in Pain Management

A new study exploring the potential of marijuana terpenes as treatments for chronic neuropathic pain suggests that these compounds could be as effective as morphine for pain relief, showing similar reductions in pain markers when administered via injection. Interestingly, when terpenes were combined with morphine, they enhanced the drug’s effectiveness as well.

The study found that, unlike morphine, none of the terpenes triggered a significant reward response, implying that they might be effective pain relievers without the risk of addiction or dysphoria. However, vaporized or orally administered terpenes did not show much impact on pain relief.

The authors highlighted that while major marijuana components, such as CBD and THC, have shown moderate effectiveness in managing severe pain, THC often has undesirable psychoactive effects. This limitation has led to a focus on other potential therapeutic compounds in marijuana, including terpenes, flavonoids and minor cannabinoids.

Terpenes, naturally occurring in many plants, such as rosemary, pine trees and oranges, are particularly abundant in marijuana, which contains about 150 different terpenes. The study suggests that this chemical diversity might contribute to the varied effects of various marijuana strains.

The research specifically investigated five terpenes: linalool, alpha-humulene, geraniol, beta-caryophyllene and beta-pinene, found in significant quantities in marijuana. The terpenes were tested on mice to evaluate their effects on inflammatory and peripheral neuropathic pain. The substances were injected into the mice’s hind paws and induced by chemotherapy medications, respectively. The terpenes were also administered orally and through vaporization.

Tests were conducted on a per-terpene basis, with 200 mg/kg of terpenes and 10 mg/kg of morphine being used for comparison. The study aimed to not only assess pain relief but also understand the mechanisms behind it. This included behavioral observations and cellular analyses, such as mRNA evaluation from flash-frozen mouse skin.

Results showed that all tested terpenes reduced neuropathic pain markers, except pinene, which did not significantly affect inflammatory pain.

Combining lower doses of terpenes with morphine appeared to enhance pain relief, indicating a potential for combination therapies that might offer better pain management while reducing the risk of opioid addiction. Regarding the potential for addiction, the study found that linalool and geraniol did not produce either an aversion or a preference in mice, suggesting they do not cause dysphoria or reward. Conversely, beta-caryophyllene and alpha-humulene showed a substantial aversive response, indicating they might be dysphoric, while beta-pinene had possible aversive side effects.

The method of administering terpenes mattered significantly. Injected terpenes were effective in reducing pain markers, whereas oral and vaporized terpenes had limited impact and sometimes caused side effects such as hypothermia. This indicates that terpenes might have restricted bioavailability when taken orally or inhaled, which could explain why some people might not experience their pain-relieving effects through these methods.

The study also explored the mechanisms behind terpene-induced pain relief, suggesting that terpenes might act as anti-inflammatory agents and interact with specific nervous system receptors. The research indicated that terpenes could act as A2AR agonists, potentially interacting with receptors in a complex manner that requires further investigation.

Overall, while the findings are promising, the authors emphasized the need for more research to fully understand how these results translate to human pain management.

This study, in a way, provides validation for companies such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) that have heavily invested in developing medical cannabis products to help patients manage their symptoms.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Daily Marijuana Use Has Now Overtaken Alcohol Use in the US

According to a recent survey, the number of Americans who use marijuana daily or almost daily has increased relative to those who use alcohol at the same frequency. The findings, which have been published in the “Addiction Journal,” are based on information gathered over the previous 40 years by the National Survey on Drug Use and Health.

According to the report, 17.7 million people used cannabis daily in 2022, overtaking the 14.7 million people who drink alcohol every day for the first time. Although alcohol is still consumed more frequently overall, the survey shows that daily cannabis consumption has significantly increased over the past few decades.

In particular, there was a 15-fold increase in the number of individuals consuming cannabis every day, or almost every day, between 1992 and 2022. Less than a million people reported using it frequently in 1992, which was the lowest number since the survey’s inception in 1979.

The chief medical officer of the medicinal cannabis startup EO Care, Dr. Brooke Worster, noted that although there are more users now for a variety of reasons, more people are freely confessing to using cannabis as a result of the stigma around it being lessened. According to Worster, the rates haven’t changed as drastically as the survey suggests.

She also noted that more than the previous 20 years, the legal marijuana market has expanded dramatically, drawing a wide variety of users, including a large number of senior citizens.

Currently, 24 states and DC allow the recreational use of cannabis, and 38 states allow it for medical use. Despite this, the federal government has been hesitant to decriminalize or fully legalize cannabis nationally.

However, a major shift occurred recently when the U.S. Department of Justice (DOJ) moved to reclassify marijuana from Schedule I of the the Controlled Substances Act (CSA) to Schedule III. President Joseph Biden acknowledged the need for reform, stating that too many lives have been destroyed by a misguided approach to cannabis.

Worster also addressed the misconception that cannabis acts as a “gateway” drug leading to the use of more dangerous substances. Decades of medical research have debunked this myth, showing that the majority of marijuana users do not progress to harder substances. Nonetheless, she cautioned that young adults and users of high-potency cannabis products are at higher risk of developing marijuana-use disorder.

Marijuana-use disorder can result in serious health and social problems that affect a person’s safety and quality of life, but it does not cause organ destruction or death such as opioid and alcohol-use disorders do.

The increasing daily use of marijuana by Americans suggests that licensed entities such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) could potentially see their sales grow steadily as more people become comfortable about using marijuana either for medicinal or recreational purposes.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Republic of South Africa President Signs Bill Legalizing Marijuana

The president of South Africa has formally signed a measure making adult use, growing and possession of cannabis legal. Just one day before the national elections, President Cyril Ramaphosa signed the Cannabis for Private Purposes Act (CfPPA) into law. The National Council of Provinces gave its support to the bill in February after it was enacted by the National Assembly in November 2023.

This legislative change has been in development for several years, beginning with a 2018 Constitutional Court ruling that declared the ban on marijuana cultivation and simple possession unconstitutional, requiring legislative amendments in two years. Although the bill to legalize cannabis was introduced in 2020, progress was slow despite the government’s intention to prioritize the cannabis sector for economic growth.

The president’s office announced in a news statement that the CfPPA will result in important regulatory changes, such as the exclusion of marijuana from the Drugs and Drug Trafficking Act. To support the industrialization of the marijuana sector, this modification will also enable changes to the Plant Breeders Rights Act, the Medicines and Related Substances Act and the Plant Improvement Act, among other laws.

The office went on to say that the bill shields children from needless exposure while offering rules for medical cannabis use for youth. It ensures that minors’ best interests are taken into consideration by providing an alternate method for resolving instances involving the unlawful use, possession or sale of cannabis. The bill also strictly prohibits the commercial sale of cannabis.

Adults are required by the new regulation to cultivate their cannabis plants and to exclusively use them inside their own homes. Furthermore, prior convictions for cannabis possession and growing may be expunged under the legislation.

Speaking on behalf of the parliament, Moloto Mothapo stated that the government hopes that the measure will open the door for further rules that will aid in the growth of the legal cannabis industry in South Africa.

President Ramaphosa outlined his plan for South Africa to join the global medical cannabis and hemp markets in his 2022 State of the Nation speech, estimating that this might generate more than 100,000 jobs. However, the main goal of the present law is to decriminalize cannabis per the 2018 court verdict, which was made in response to a decision made by a lower court in the province of the Western Cape.

As in South Africa, the Supreme Court in Mexico declared in 2018 that the prohibition of marijuana is unconstitutional, forcing legislators to amend the legislation. Mexico has not yet fully implemented the reform despite recent sessions seeing some progress in this area.

The signs of the wave triggering change in marijuana policy in Africa as well suggests that major entities such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) could in future have global markets to serve as the trade in this hitherto outlawed substance becomes more commonplace.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Completes Cargo Management Group Acquisition, Focuses on Long-Term Shareholder Value

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, has completed the acquisition of Cargo Management Group, a multifaceted logistics and trucking operation. According to the announcement, the transaction involved using 10% of the profits from GTVH’s logistics business to buy back and retire GTVH stock, which effectively reduced the number of outstanding shares on a consistent basis as profits are realized. This move represents Golden Triangle Ventures focus on driving long-term value for its shareholders. The company noted that Cargo Management Group reported nearly $3 million in revenue for 2023; the acquisition is expected to streamline internal operations, yield significant cost savings and bolster cash flow, thereby enhancing the Golden Triangle’s business margins. “This initiative marks the first of several strategies we plan to implement that aim to optimize our capital structure within GTV,” said Golden Triangle Ventures president Steffan Dalsgaard in the press release. “Our goal is to develop true fundamental business activities that support all of our operations. We have successfully implemented the first part of our four-pillar business model that supports Lavish Entertainment and our flagship Destino Ranch project, and our team is now focused on executing a series of other promising developments. These efforts are designed to further our objective of increasing shareholder value across all facets of our company.”

To view the full press release, visit https://cnw.fm/8X6q8

About Golden Triangle Ventures Inc.

Golden Triangle Ventures is a multifaceted consulting company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen its products and/or services. The three points of the Golden Triangle exclusively represent the three sectors the company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the company. An amazing team of professionals support each division and continue to help Golden Triangle Ventures grow daily. For more information about the company, please visit www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Alternative Products Expo to Showcase Tradeshow At Houston

Cultivators, manufacturers, entrepreneurs, traders, and enthusiasts, are invited to attend the Alternative Products Expo being held June 20-22, 2024, at the George R. Brown Center, in Houston. With its dynamic vibe of food, culture, art, and pulsating nightlife, Houston is the perfect venue for the Alternative Products Expo.

The Altpro Expo in Houston is hosted by USA CBD Expo, America’s leading CBD and Hemp Expo event organizers. Over recent years, they have expanded to include the full alternative products range ecosystem. Organized by ZJ Events, the Expo caters to the industry’s best CBD traders, manufacturers, and enthusiasts offering an exciting learning experience under a common arena.

With the Houston smoke shop scene in full swing, this year’s Expo is expected to showcase over 500 smoke shops, with numbers rising every year. Both emerging and seasoned brands benefit tremendously by exhibiting their products and services to the Expo’s crowd of enthusiastic audiences.

The Alternative Products Expo offers a phenomenal networking opportunity, where industry people can connect and collaborate with leading brand experts and manufacturers for long-term ROI. Attendees will discover the latest trends and novel ideas currently leading the industry. Exhibitors can showcase their unique offerings to grab a bigger share of the market. Traders can leverage the best show deals as fresh products are introduced with limited-time offers. Also, get updated on the latest regulations and learn the future course of the Alternative Products markets.

Trinity Hemp is the presenting sponsor of Alternative Products Expo Houston.

To learn more, please visit https://cnw.fm/cCKMY

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

  • Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24
  • The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents
  • The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals
  • According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, started 2024 with a portfolio of 38 patents granted worldwide, having received ten new granted patents during 2023, the most yet in a single year. That patent portfolio, company CEO Chris Bunka explained in his 2024 letter to shareholders, provides vital support for Lexaria’s commercialization efforts as it forms “the foundation upon which future commercial relationships are built.” Yet, according to the letter, the company continues to expect additional patents to be awarded in the future and retains many valid patent applications throughout the world (https://cnw.fm/Bb3nv).

This year, the company has received five new patents, growing its portfolio to 43 granted patents worldwide. This follows the April receipt of three new patents and the most recent announcement of two important new patent awards captured in a May 2024 news release.

According to the announcement, Lexaria received a new granted patent in its patent family #21: Compositions and Methods for Treating Hypertension. This is the company’s third granted U.S. patent in this patent family. Lexaria also reported the receipt of a new granted patent in its patent family #24: Compositions and Methods for Treating Epilepsy. This is the company’s third granted U.S. patent in this patent family (https://cnw.fm/6eFfU).

The company’s growing list of granted patents results from early and ongoing R&D. According to Mr. Bunka, Lexaria uses study-dependent data from studies to confidently support its patent applications. But besides serving the “purpose of allowing us to more confidently apply for patent protection using the study-dependent data,” the studies provide data to potentially support further investigations and discoveries, as well as potential approvals by the U.S. Food and Drug Administration (“FDA”).

This approach, coupled with the long-term vision, has enabled the company to investigate the capabilities of various active pharmaceutical ingredients processed using its patented DehydraTECH(TM) drug delivery technology in human and animal studies. For instance, Lexaria has investigated the ability of DehydraTECH-processed cannabidiol (“CBD”) to potentially treat hypertension in humans and mitigate epileptic seizures in rodents. These applications are partly or wholly protected by the recently granted patents.

Lexaria has repeatedly demonstrated that DehydraTECH-CBD has shown an ability to lower blood pressure in both acute dosing in hypertension and over a 5-week study duration. In a series of four hypertension studies, the company evidenced DehydraTECH-CBD’s ability to lower human blood pressure (https://cnw.fm/YuYG6), including in cases where the treatment was administered over an extended period (https://cnw.fm/ukRzo). The fourth study also led to the discovery of a potentially novel mechanism of action of DehydraTECH-CBD (https://cnw.fm/MjOjt).

These positive results encouraged the company to begin the process of seeking approval from the FDA to conduct a Phase 1b randomized, double-blind, placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD for the treatment of stage 1 or 2 hypertension. The company received earlier this year the FDA clearance to conduct the study (https://cnw.fm/Yo9IO) and will provide updates on the status of this planned study in due course.

Beyond the treatment of hypertension, Lexaria has demonstrated, through an animal study, that DehydraTECH-CBD reduces or eliminates seizure activity in animals and, in some cases, even surpasses the performance of Epidiolex(R), one of the world’s leading anti-seizure medications. The company also reported that DehydraTECH-CBD suppresses body weight, improves triglyceride/cholesterol levels, and reduces blood glucose levels in an animal diabetes study.

The successes of these animal studies have supported the possibility of conducting additional human clinical studies of DehydraTECH-CBD. In addition to investigating DehydraTECH-CBD’s capabilities, Lexaria is also looking at the potential application of its drug delivery technology to GLP-1 drugs.

Supported by a robust growing portfolio of granted patents and encouraged by the positive results from its R&D activities, Lexaria continues to forge ahead, aiming to achieve its future business objectives.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Alternative Products Expo Returns to Texas for Flagship Global Counterculture Event

Alternative Products Expo (Alt Pro Expo) is preparing to kick off its next in a series of blowout events across North and South America. Presented by ZJ Evets, Alt Pro Expo is slated for June 20–22, 2024, in Houston, Texas. Through the years, Alt Pro Expo has built a reputation for creating a flagship series of events in the global counterculture industry. The agenda for the networking festival includes invaluable education while the exhibit area spotlights an incredible portfolio of innovative products, including vape and hemp products, CBD, disposables, kratom, mushrooms, functional beverages, dietary supplements, nootropics, nicotine replacement, energy enhancers, mood changers and other accessories. The event offers an unparalleled opportunity for hundreds of top manufacturers, buyers, suppliers, innovators, vendors, researchers, budding entrepreneurs and seasoned industry professionals to gather together. “The Alternative Products Expo is the flagship series for the global counterculture industry and is the preeminent platform for nurturing professional networks, building market presence, and fine-tuning market entry strategies,” said Alt Pro Expo director of partnerships Sebastian Carmona in the press release. “Following the raging success of the Dallas event last year, we are thrilled to be returning to the great state of Texas to help drive participation and innovation in the vape, smoke shop and the broader alternative products sector. The upcoming expo is a must-attend for fresh business owners and vendors, established industry players, enthusiastic consumers, and curious newcomers.”

To attend the event, visit https://cnw.fm/fTtra

To view the full press release, visit https://cnw.fm/WVLn7

About Alternative Products Expo

Alternative Products Expo, formerly USA CBD Expo, is a production of ZJ Events. Company founders were once exhibitors who, after attending countless trade show events, saw an opportunity to build upon their experience and create an event that combined the best they had seen, with their own notion of what was missing in these business gatherings. By bringing the alternative community together, the company seeks to provide industry professionals from all corners of the market with an immersive and unique opportunity for networking and business expansion. For more information about the company, visit www.AltProExpo.com.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN